Professor | Dedong Cao | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Dedong Cao
Contact Information	caodedong123@whu.edu.cn
Language ability	English, Chinese
Province	Hubei

Upload Avatar (500 x 500)

Name

Dedong Cao

Contact Information

caodedong123@whu.edu.cn

Language ability

English, Chinese

Province

Hubei

University/Lab Affiliation and Title	Wuhan University
Faculty	Medical School
Academic Background & Achievements	2004.09-2009.06 Bachelor of Clinical Medicine from Second Clinical College of Yunyang Medical College 2009.09-2011.06 Master of Oncology from First Clinical College of Wuhan University 2011.09-2014.06 PhD in Internal Medicine from First Clinical College of Tongji Medical College, Huazhong University of Science and Technology
Work Experience	2014.07-2014.10 Physician, Oncology Department, Renmin Hospital, Wuhan University 2014.11-2017.10 Attending Physician, Oncology Department, Renmin Hospital, Wuhan University 2017.11-2018.01 Associate Chief Physician, Oncology Department, Renmin Hospital, Wuhan University 2018.02-2019.07 Visiting Scholar, Fred Hutchinson Cancer Research Center, USA 2019.08-2020.01 Associate Chief Physician, Oncology Department, Renmin Hospital, Wuhan University 2020.02-2020.04 Associate Chief Physician, Fever Clinic and Fever Observation Ward, Renmin Hospital, Wuhan University 2020.05-2022.11 Associate Chief Physician, Oncology Department, Renmin Hospital, Wuhan University 2022.04-present Deputy Director, Medical Department, Renmin Hospital, Wuhan University 2022.11-present Chief Physician, Associate Professor, Oncology Department, Renmin Hospital, Wuhan University
Awards	Mechanism and Precision Treatment of Primary Liver Cancer, First Prize of Hubei Province Science and Technology Progress Award Mechanism and Clinical Application of Recombinant Human Endostatin (Endostar) to Increase Radiotherapy Sensitivity, Third Prize of Hubei Province Science and Technology Progress Award Mechanism and Clinical Application of Recombinant Human Endostatin (Endostar) to Increase Radiotherapy Sensitivity, Third Prize of Wuhan Science and Technology Progress Award

University/Lab Affiliation and Title

Wuhan University

Faculty

Medical School

Academic Background & Achievements

2004.09-2009.06 Bachelor of Clinical Medicine from Second Clinical College of Yunyang Medical College
2009.09-2011.06 Master of Oncology from First Clinical College of Wuhan University
2011.09-2014.06 PhD in Internal Medicine from First Clinical College of Tongji Medical College, Huazhong University of Science and Technology

Work Experience

2014.07-2014.10 Physician, Oncology Department, Renmin Hospital, Wuhan University
2014.11-2017.10 Attending Physician, Oncology Department, Renmin Hospital, Wuhan University
2017.11-2018.01 Associate Chief Physician, Oncology Department, Renmin Hospital, Wuhan University
2018.02-2019.07 Visiting Scholar, Fred Hutchinson Cancer Research Center, USA
2019.08-2020.01 Associate Chief Physician, Oncology Department, Renmin Hospital, Wuhan University
2020.02-2020.04 Associate Chief Physician, Fever Clinic and Fever Observation Ward, Renmin Hospital, Wuhan University
2020.05-2022.11 Associate Chief Physician, Oncology Department, Renmin Hospital, Wuhan University
2022.04-present Deputy Director, Medical Department, Renmin Hospital, Wuhan University
2022.11-present Chief Physician, Associate Professor, Oncology Department, Renmin Hospital, Wuhan University

Awards

Mechanism and Precision Treatment of Primary Liver Cancer, First Prize of Hubei Province Science and Technology Progress Award
Mechanism and Clinical Application of Recombinant Human Endostatin (Endostar) to Increase Radiotherapy Sensitivity, Third Prize of Hubei Province Science and Technology Progress Award
Mechanism and Clinical Application of Recombinant Human Endostatin (Endostar) to Increase Radiotherapy Sensitivity, Third Prize of Wuhan Science and Technology Progress Award

Areas of Focus	Radiotherapy Sensitization Strategies and Mechanisms Tumor Metabolism and Immunotherapy Evidence-Based Medicine in Oncology
Publications	The application of nanoparticles in immunotherapy for hepatocellular carcinoma, Hu X, Zhu H, He X, Chen J, Xiong L, Shen Y, Li J, Xu Y, Chen W, Liu X, Cao D, Xu X, 2023 Tumor-Suppressive and Oncogenic Roles of microRNA-149-5p in Human Cancers, Shen Y, Zhao N, Zhao N, Hu X, He X, Xu Y, Chen J, Chen W, Liu X, Zhou Z, Cao D, Xu X, 2022 Phagocytosis-Regulators-Based Signature to Predict the Prognosis and Chemotherapy Resistance for Breast Cancer Patients, Feng J, Ren J, Li X, Zhang X, Yang Q, Wu Z, Cui L, Liao L, Gong Y, Cao D, 2022 The association between antibiotics use and outcome of cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis, Xu H, Xu X, Wang H, Ge W, Cao D, 2020 High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients, Cao D, Xu H, Xu X, Guo T, Ge W, 2019 The association between immune-related adverse events and the prognosis of solid cancer patients treated with immunotherapy: a systematic review and meta-analysis, Xu H, Xu X, Ge W, Lei J, Cao D, 2020 A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies, D Cao, H Xu, X Xu, T Guo, W Ge, 2018 The effects of prophylactic cranial irradiation versus control on survival of patients with extensive-stage small-cell lung cancer: a meta-analysis of 14 trials, W Ge, H Xu, Y Yan, D Cao, 2018 Assessing Potential Factors Influencing the Efficacy of Immune Checkpoint Inhibitors with Radiation in Advanced Non-Small-Cell Lung Cancer Patients: A Systematic Review and Meta-Analysis, Xu H, Cao D, Zhou D, He A, Ge W, Xu X, 2023 Bevacizumab improves survival in metastatic colorectal cancer patients with primary tumor resection: A meta-analysis, Cao D, Zheng Y, Xu H, Ge W, Xu X, 2019 The prognostic role of neutrophil-to-lymphocyte ratio and C-reactive protein in metastatic colorectal cancer using regorafenib: a systematic review and meta-analysis, Zhao N, Xu H, Zhou D, Xu X, Ge W, Cao D, 2022 胸腔内注射榄香烯治疗肺癌恶性胸腔积液疗效的系统评价, 曹德东,徐敏,蒋振旻,等, 2018

Areas of Focus

Radiotherapy Sensitization Strategies and Mechanisms
Tumor Metabolism and Immunotherapy
Evidence-Based Medicine in Oncology

Publications

The application of nanoparticles in immunotherapy for hepatocellular carcinoma, Hu X, Zhu H, He X, Chen J, Xiong L, Shen Y, Li J, Xu Y, Chen W, Liu X, Cao D, Xu X, 2023
Tumor-Suppressive and Oncogenic Roles of microRNA-149-5p in Human Cancers, Shen Y, Zhao N, Zhao N, Hu X, He X, Xu Y, Chen J, Chen W, Liu X, Zhou Z, Cao D, Xu X, 2022
Phagocytosis-Regulators-Based Signature to Predict the Prognosis and Chemotherapy Resistance for Breast Cancer Patients, Feng J, Ren J, Li X, Zhang X, Yang Q, Wu Z, Cui L, Liao L, Gong Y, Cao D, 2022
The association between antibiotics use and outcome of cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis, Xu H, Xu X, Wang H, Ge W, Cao D, 2020
High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients, Cao D, Xu H, Xu X, Guo T, Ge W, 2019
The association between immune-related adverse events and the prognosis of solid cancer patients treated with immunotherapy: a systematic review and meta-analysis, Xu H, Xu X, Ge W, Lei J, Cao D, 2020
A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies, D Cao, H Xu, X Xu, T Guo, W Ge, 2018
The effects of prophylactic cranial irradiation versus control on survival of patients with extensive-stage small-cell lung cancer: a meta-analysis of 14 trials, W Ge, H Xu, Y Yan, D Cao, 2018
Assessing Potential Factors Influencing the Efficacy of Immune Checkpoint Inhibitors with Radiation in Advanced Non-Small-Cell Lung Cancer Patients: A Systematic Review and Meta-Analysis, Xu H, Cao D, Zhou D, He A, Ge W, Xu X, 2023
Bevacizumab improves survival in metastatic colorectal cancer patients with primary tumor resection: A meta-analysis, Cao D, Zheng Y, Xu H, Ge W, Xu X, 2019
The prognostic role of neutrophil-to-lymphocyte ratio and C-reactive protein in metastatic colorectal cancer using regorafenib: a systematic review and meta-analysis, Zhao N, Xu H, Zhou D, Xu X, Ge W, Cao D, 2022
胸腔内注射榄香烯治疗肺癌恶性胸腔积液疗效的系统评价, 曹德东,徐敏,蒋振旻,等, 2018

Radiotherapy Sensitization Mechanisms Tumor Metabolism Immunotherapy Evidence-Based Medicine Oncology Clinical Trials

Bin Ren - Wuhan University

Yong Huang - Wuhan University

Xu Binghe - Wuhan University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us